Amre Nouh, MD
Neurology · Weston, FLNPI 1306162474
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,892 of the $52,971 with a category attached, or 82.9%. Genentech USA, Inc. accounts for 64.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $48,673 and has fallen 99.7% since, to $151 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $778.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$34K
- Portola Pharmaceuticals, LLC$16K
- F. Hoffmann-la Roche AG$2K
- Boston Scientific$178
- Argenx US, Inc.$125
- AstraZeneca$112
- plus $218 from 7 others
Across 10 payments — averaging $954.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$7K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Speaking & faculty fees$43,89283%
- Travel & lodging$6,99413%
- Food & beverage$2,0844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 27 | $34,171 |
| Portola Pharmaceuticals, LLC | 20 | $16,400 |
| F. Hoffmann-la Roche AG | 4 | $1,767 |
| Boston Scientific | 6 | $178 |
| Argenx US, Inc. | 1 | $125 |
| AstraZeneca | 1 | $112 |
| AbbVie | 3 | $54 |
| Chiesi USA, Inc. | 1 | $45 |
| Revance Therapeutics, Inc. | 1 | $29 |
| EMD Serono, Inc. | 1 | $25 |
| UCB, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Biogen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$16,095
- Activase$13,938
- TNKase$1,767
- VYVGART HYTRULO$125
How this compares
$52,971 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 25 | $328 |
| Levetiracetam | 13 | $239 |
| Duloxetine Hcl | 14 | $193 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $163 |
| ClopidogrelClopidogrel Bisulfate | 12 | $141 |
| Baclofen | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other neurology in Weston
- Paunel AgyeiWeston$206K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.